Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00662688 |
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with chemotherapy. It is not yet known whether gemcitabine is more effective when given alone or together with dalteparin and/or capecitabine in treating patients with pancreatic cancer.
PURPOSE: This randomized phase III trial is studying whether dalteparin prevents blood clots in patients with pancreatic cancer receiving treatment with different combinations of gemcitabine and capecitabine.
Condition | Intervention | Phase |
---|---|---|
Chemotherapeutic Agent Toxicity Pancreatic Cancer Thromboembolism |
Drug: capecitabine Drug: dalteparin Drug: gemcitabine hydrochloride Genetic: mutation analysis Other: laboratory biomarker analysis |
Phase III |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Active Control |
Official Title: | Chemotherapy With or Without Preventive Anticoagulation for Metastatic Cancer of the Pancreas |
Estimated Enrollment: | 136 |
Study Start Date: | October 2007 |
Estimated Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study. Patients are stratified according to participating center and WHO performance status (0-1 vs 2). Patients are randomized to 1 of 4 treatment arms.
Blood and plasma samples are obtained at baseline and periodically during study. Blood is examined for biomarkers, resistance to activated protein C, and mutations (Leiden V factor, mutation G20210A, and the factor II gene). Thrombin generation and factors VIIa and VIII are assessed in plasma.
After completion of study therapy, patients are followed periodically.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma of the pancreas
PATIENT CHARACTERISTICS:
No other cancer in the past 5 years except the following cancers, provided they have been completely resected:
PRIOR CONCURRENT THERAPY:
France | |
Centre Hospitalier Intercommunal Le Raincy - Montfermeil | Recruiting |
Montfermeil, France, 93370 | |
Contact: Contact Person 33-1-41-70-80-00 | |
CHU Pitie-Salpetriere | Recruiting |
Paris, France, 75651 | |
Contact: Contact Person 33-1-42-16-00-00 | |
Hopital Bichat - Claude Bernard | Recruiting |
Paris, France, 75018 | |
Contact: Contact Person 33-1-4025-7000 | |
Hopital Foch | Recruiting |
Suresnes, France, 92151 | |
Contact: Contact Person 33-8-26-20-72-20 | |
Hopital Saint Antoine | Recruiting |
Paris, France, 75571 | |
Contact: Contact Person 33-1-4928-2336 benoist.chabaudel@sat.aphp.fr |
Principal Investigator: | Benoist Chibauldel, MD | Hopital Saint Antoine |
Study ID Numbers: | CDR0000593019, GERCOR-PAM07-D07-2, EUDRACT 2007-002115-59, EU-20837, PFIZER-GERCOR-PAM07-D07-2 |
Study First Received: | April 18, 2008 |
Last Updated: | July 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00662688 History of Changes |
Health Authority: | Unspecified |
thromboembolism chemotherapeutic agent toxicity adenocarcinoma of the pancreas stage IV pancreatic cancer recurrent pancreatic cancer |
Antimetabolites Anti-Infective Agents Immunologic Factors Pancreatic Neoplasms Fibrinolytic Agents Pancrelipase Thromboembolism Fibrin Modulating Agents Neoplasm Metastasis Gemcitabine Endocrine Gland Neoplasms Capecitabine Anticoagulants Digestive System Neoplasms Vascular Diseases |
Endocrine System Diseases Cardiovascular Agents Antiviral Agents Immunosuppressive Agents Thrombosis Recurrence Embolism and Thrombosis Digestive System Diseases Radiation-Sensitizing Agents Embolism Dalteparin Pancreatic Diseases Gastrointestinal Neoplasms Endocrinopathy Adenocarcinoma |
Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Pancreatic Neoplasms Hematologic Agents Physiological Effects of Drugs Fibrinolytic Agents Thromboembolism Fibrin Modulating Agents Neoplasms by Site Therapeutic Uses Cardiovascular Diseases |
Gemcitabine Endocrine Gland Neoplasms Capecitabine Anticoagulants Digestive System Neoplasms Vascular Diseases Endocrine System Diseases Enzyme Inhibitors Cardiovascular Agents Immunosuppressive Agents Antiviral Agents Thrombosis Pharmacologic Actions Embolism and Thrombosis Neoplasms |